These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37697037)

  • 1. RNA as an off-target for FDA-approved drugs.
    Fullenkamp CR; Schneekloth JS
    Nat Chem; 2023 Oct; 15(10):1329-1331. PubMed ID: 37697037
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
    Zhu Y; Hu X
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.
    Etan T; Amir E; Tibau A; Yerushalmi R; Moore A; Shepshelovich D; Goldvaser H
    Cancer Treat Rev; 2020 Dec; 91():102113. PubMed ID: 33128993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale bioactivity analysis of the small-molecule assayed proteome.
    Backman TW; Evans DS; Girke T
    PLoS One; 2017; 12(2):e0171413. PubMed ID: 28178331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis.
    Aungsumart S; Youngkong S; Dejthevaporn C; Chaikledkaew U; Thadanipon K; Tansawet A; Khieukhajee J; Attia J; McKay GJ; Thakkinstian A
    Front Neurol; 2023; 14():1166490. PubMed ID: 37082442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
    Chen DT; Wynia MK; Moloney RM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Computational Approach to Predict Off-Target Interactions for Small Molecules.
    Rao MS; Gupta R; Liguori MJ; Hu M; Huang X; Mantena SR; Mittelstadt SW; Blomme EAG; Van Vleet TR
    Front Big Data; 2019; 2():25. PubMed ID: 33693348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use-Patient Harms and Prescriber Responsibilities.
    Van Norman GA
    JACC Basic Transl Sci; 2023 Feb; 8(2):224-233. PubMed ID: 36908673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.
    Lim M; Shulman DS; Roberts H; Li A; Clymer J; Bona K; Al-Sayegh H; Ma C; DuBois SG
    Cancer Med; 2020 Sep; 9(18):6658-6666. PubMed ID: 32750219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
    Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
    Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The response rate of alternative treatments for drugs approved on the basis of response rate.
    Haslam A; Gill J; Prasad V
    Int J Cancer; 2021 Feb; 148(3):713-722. PubMed ID: 32700797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network analysis of FDA approved drugs and their targets.
    Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R
    Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.